Posts Tagged ‘Nanomedicine’

Gold nanostars shuttled to cancer cell nucleus to release drug

One of the most promising current applications of nanotechnology to medicine is the use of nanoparticles to specifically target drug therapy to cancer cells. A variety of different types of nanoparticles using different drug delivery strategies are being investigated, including one type using biopolymers that we described here last week. Another report shows that a very different type of nanoparticle, composed of gold, works by delivering a drug directly to the nucleus of cancer cells. A hat tip to ScienceDaily for reprinting this news release from Northwestern University written by Megan Fellman “ Tiny hitchhikers attack cancer cells: Gold nanostars first to deliver drug directly to cancer cell nucleus “: Nanotechnology offers powerful new possibilities for targeted cancer therapies, but the design challenges are many. Northwestern University scientists now are the first to develop a simple but specialized nanoparticle that can deliver a drug directly to a cancer cell’s nucleus — an important feature for effective treatment. They also are the first to directly image at nanoscale dimensions how nanoparticles interact with a cancer cell’s nucleus. “Our drug-loaded gold nanostars are tiny hitchhikers,” said Teri W. Odom, who led the study of human cervical and ovarian cancer cells. “They are attracted to a protein on the cancer cell’s surface that conveniently shuttles the nanostars to the cell’s nucleus. Then, on the nucleus’ doorstep, the nanostars release the drug, which continues into the nucleus to do its work.” … Using electron microscopy, Odom and her team found their drug-loaded nanoparticles dramatically change the shape of the cancer cell nucleus. What begins as a nice, smooth ellipsoid becomes an uneven shape with deep folds. They also discovered that this change in shape after drug release was connected to cells dying and the cell population becoming less viable — both positive outcomes when dealing with cancer cells. The results are published in the journal ACS Nano [ abstract ]. Since this initial research, the researchers have gone on to study effects of the drug-loaded gold nanostars on 12 other human cancer cell lines. The effect was much the same. “All cancer cells seem to respond similarly,” Odom said. “This suggests that the shuttling capabilities of the nucleolin protein for functionalized nanoparticles could be a general strategy for nuclear-targeted drug delivery.” The nanoparticle is simple and cleverly designed. It is made of gold and shaped much like a star, with five to 10 points. (A nanostar is approximately 25 nanometers wide.) The large surface area allows the researchers to load a high concentration of drug molecules onto the nanostar. Less drug would be needed than current therapeutic approaches using free molecules because the drug is stabilized on the surface of the nanoparticle. The drug used in the study is a single-stranded DNA aptamer called AS1411. Approximately 1,000 of these strands are attached to each nanostar’s surface. The DNA aptamer serves two functions: it is attracted to and binds to nucleolin, a protein overexpressed in cancer cells and found on the cell surface (as well as within the cell). And when released from the nanostar, the DNA aptamer also acts as the drug itself. Bound to the nucleolin, the drug-loaded gold nanostars take advantage of the protein’s role as a shuttle within the cell and hitchhike their way to the cell nucleus. The researchers then direct ultrafast pulses of light — similar to that used in LASIK surgery — at the cells. The pulsed light cleaves the bond attachments between the gold surface and the thiolated DNA aptamers, which then can enter the nucleus. In addition to allowing a large amount of drug to be loaded, the nanostar’s shape also helps concentrate the light at the points, facilitating drug release in those areas. Drug release from nanoparticles is a difficult problem, Odom said, but with the gold nanostars the release occurs easily. That the gold nanostar can deliver the drug without needing to pass through the nuclear membrane means the nanoparticle is not required to be a certain size, offering design flexibility. Also, the nanostars are made using a biocompatible synthesis, which is unusual for nanoparticles. Odom envisions the drug-delivery method, once optimized, could be particularly useful in cases where tumors are fairly close to the skin’s surface, such as skin and some breast cancers. (The light source would be external to the body.) Surgeons removing cancerous tumors also might find the gold nanostars useful for eradicating any stray cancer cells in surrounding tissue. A particular advantage of these nanostars is that the plasmonic electrons produced on the surface of the nanostars by the laser solves the problem of how to efficiently discharge the drug target from the nanoparticle vehicle. —James Lewis, PhD

Nanotechnology, digital fabrication, and innovation at TED

John Walker, a longtime friend to nanotech and Foresight, sends this news about a TEDxBerkeley video: Carl Bass, successor to the successor to the successor to me as CEO of Autodesk got up in front of an audience and spoke on “The Five New Rules of Innovation” among which was nanoscale and bio-inspired structures. Unlike when I did it all those many years ago, nobody giggled. And they say there isn’t progress! Video (17 minutes–the nano bit is short, but it’s there): John Walker’s thoughts on nanotechnoloogy were published about 22 years ago in a Foresight Briefing “ What Next? Nanotechnology for Manufacturing “. The definitive copy of this essay, with the complete set of illustrations, is available on John Walker’s Web site.

DNA nanotechnology-based nanorobot delivers cell suicide message to cancer cells

Image courtesy of the Wyss Institute “ The nanosized robot was created in the form of an open barrel whose two halves are connected by a hinge. The DNA barrel, which acts as a container, is held shut by special DNA latches that can recognize and seek out combinations of cell-surface proteins, including disease markers. This image was created by Campbell Strong, Shawn Douglas, and Gaël McGill using Molecular Maya and cadnano. “ DNA nanotechnology is not only a very promising path toward productive nanosystems and atomically precise manufacturing, but also a path to increasingly sophisticated DNA molecular machines for near-term drug delivery applications in nanomedicine. A recent advance comprises an autonomous DNA nanorobot incorporating a DNA origami chasis and DNA aptamer locks functioning as logical AND gates that are unlocked after the aptamers bind a protein target on the target cell, allowing the nanorobot to discharge its therapeutic cargo. A hat tip to KurzweilAI.net for reprinting this Harvard Gazette news release written by Twig Mowatt “ Sending DNA robot to do the job: Technology has potential to seek out cancer cells, cause them to self-destruct “: Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a robotic device made from DNA that could potentially seek out specific cell targets within a complex mixture of cell types and deliver important molecular instructions, such as telling cancer cells to self-destruct. Inspired by the mechanics of the body’s own immune system, the technology might one day be used to program immune responses to treat various diseases. The research findings appear today in Science ["A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads" abstract ; full text available for fair use on Church lab web site]. Using the DNA origami method, in which complex 3-D shapes and objects are constructed by folding strands of DNA, Shawn Douglas, a Wyss Technology Development Fellow, and Ido Bachelet, a former Wyss postdoctoral fellow who is now an assistant professor in the Faculty of Life Sciences and the Nano-Center at Bar-Ilan University in Israel, created a nanosized robot in the form of an open barrel whose two halves are connected by a hinge. The DNA barrel, which acts as a container, is held shut by special DNA latches that can recognize and seek out combinations of cell-surface proteins, including disease markers. When the latches find their targets, they reconfigure, causing the two halves of the barrel to swing open and expose its contents, or payload. The container can hold various types of payloads, including specific molecules with encoded instructions that can interact with specific cell surface signaling receptors. Douglas and Bachelet used this system to deliver instructions, which were encoded in antibody fragments, to two different types of cancer cells — leukemia and lymphoma. In each case, the message to the cell was to activate its “suicide switch” — a standard feature that allows aging or abnormal cells to be eliminated. And because leukemia and lymphoma cells speak different languages, the messages were written in different antibody combinations. … “We can finally integrate sensing and logical computing functions via complex, yet predictable, nanostructures — some of the first hybrids of structural DNA, antibodies, aptamers, and metal atomic clusters — aimed at useful, very specific targeting of human cancers and T-cells,” said George Church, a Wyss core faculty member and professor of genetics at Harvard Medical School, who is principal investigator on the project. … A key feature of this work is that the DNA aptamer changes structure upon binding its target so it releases its hold on the complementary part of the DNA latch. Since two DNA latches hold the nanorobot in a closed configuration, the latches can be programmed to both respond to the same cell surface target, or to each respond to a different target so that both targets would need to be on the cell to activate the nanorobot to open and allow the payload molecules to bind their targets. This logical AND function allows for much greater specificity in recognizing target cells. As the authors conclude, “These findings demonstrate that the robots can induce a variety of tunable changes in cell behavior.” Conceivably a similar mechanism could be used in an atomically precise manufacturing operation in which DNA nanorobots could add a payload molecule to a workpiece depending on whether both of two specific molecular signals on the workpiece were present. —James Lewis

First Master’s of Science in Nanomedicine degree program in US announced

We received this announcement of the new M.S. in Nanomedicine program from Radiological Technologies University – VT : Radiological Technologies University VT, located in South Bend, Indiana is pleased to announce the approval of the first Master’s of Science in Nanomedicine degree program in the country. The formal approval was granted today through the Indiana Commission for Postsecondary Proprietary Education. Nanomedicine is the medical application of Nanotechnology which focuses its work at the cellular level to do everything from repairing tissue, to cleaning arteries, to attacking cancer cells and viruses like AIDS. The RTU Nanomedicine program is the first of its kind in the country by combining Nanotechnology with an emphasis on Medical Physics. Radiological Technologies University offers degree programs ranging from a Bachelor’s degree in Medical Dosimetry to Master’s of Science degrees in Medical Dosimetry, Medical Physics, Medical Health Physics, and Nanomedicine. Although Foresight has no information about the details of this nanomedicine program, just one item from the NCI Alliance for Nanotechnology in Cancer news archive highlights the potential of nanomedicine, specifically the application of nanoparticles to cancer therapy. From “ Nanoparticles seek and destroy drug-resistant glioblastoma “: Glioblastoma is one of the most aggressive forms of brain cancer. Rather than presenting as a well-defined tumor, glioblastoma will often infiltrate the surrounding brain tissue, making it extremely difficult to treat surgically or with chemotherapy or radiation. Likewise, several mouse models of glioblastoma have proven completely resistant to all treatment attempts. In a new study, a team led by scientists at Sanford-Burnham Medical Research Institute (SBMRI) and the Salk Institute for Biological Studies developed a method to combine a tumor-homing peptide, a cell-killing peptide, and a nanoparticle that both enhances tumor cell death and allows the researchers to image the tumors. When used to treat mice with glioblastoma, this new nanosystem eradicated most tumors in one model and significantly delayed tumor development in another. These findings were published in the Proceedings of the National Academy of Sciences of the USA [ abstract ]. “This is a unique nanosystem for two reasons,” said project leader Erkki Ruoslahti of the SBMRI. “First, linking the cell-killing peptide to nanoparticles made it possible for us to deliver it specifically to tumors, virtually eliminating the killer peptide’s toxicity to normal tissues. Second, ordinarily researchers and clinicians are happy if they are able to deliver more drugs to a tumor than to normal tissues. We not only accomplished that, but were able to design our nanoparticles to deliver the killer peptide right where it acts, at the mitochondria, the cell’s energy-generating center.” The nanosystem developed in this study is made up of three elements. First, a nanoparticle acts as the carrier framework for an imaging agent and for two peptides. One of these peptides guides the nanoparticle and its payload specifically to cancer cells and the blood vessels that feed them by binding cell surface markers that distinguish them from normal cells. This same peptide also drives the whole system inside these target cells, where the second peptide wreaks havoc on the mitochondria, triggering cellular suicide through a process known as apoptosis. Together, these peptides and nanoparticles proved extremely effective at treating two different mouse models of glioblastoma. In the first model, treated mice survived significantly longer than untreated mice. In the second model, untreated mice survived for only eight to nine weeks. In sharp contrast, treatment with this nanosystem cured all but one of ten mice. What’s more, in addition to providing therapy, the nanoparticles could aid in diagnosing glioblastoma; they are made of iron oxide, which makes them and the tumors they target visible by magnetic resonance imaging. In a final twist, the researchers made the whole nanosystem even more effective by administering it to the mice in conjunction with a third peptide. Ruoslahti and his team previously showed that this peptide, known as iRGD, helps co-administered drugs penetrate deeply into tumor tissue. iRGD has been shown to substantially increase treatment efficacy of various drugs against human breast, prostate, and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug. Here, iRGD enhanced nanoparticle penetration and therapeutic efficacy. In this study, the researchers tested their nanoparticles on mice that developed glioblastomas with the same characteristics as observed in humans with the disease. Once the nanoparticles reached the tumors’ blood vessels, they delivered their payload directly to the cell’s power producer, the mitochondria. By destroying the blood vessels and also some surrounding tumor cells, the investigators found they were able to cure some mice and extend the lifespan of the rest.”

Foresight co-founder among panelists discussing role of technology in human existence

Foresight Institute Co-Founder and Past President Christine Peterson was among four panelists addressing the role of technology in human existence for a Stanford University Continuing Studies series. From a report in The Stanford Daily by Marshall Watkins “ Bay Area thinkers ponder ‘life’ “: Christine Peterson, co-founder and president of The Foresight Institute, a public interest group seeking to educate the community on forthcoming technological advances, emphasized the increasingly prominent role that nanotechnology has come to play. Peterson noted that nanotechnology has the potential to create new materials and make vast advances without the side effects, such as pollution, that would currently ensue. She allowed, however, that the near-invisible and highly sensitive technology might enable intrusions on privacy. “We need to know what data is collected,” Peterson said, “how it is used and how long it is retained. We have those rights.” Peterson highlighted the medical benefits of nanotechnology, noting, “The ability to control atoms and molecules would mean that there really isn’t a physical illness [that] we wouldn’t be able to address.” The report quotes the moderator of the panel, author Piero Scaruffi, as stating that the four panelists were picked because “They discussed life as in the future, rather than life as in the past.” We can certainly expect that life after advanced nanotechnology has been developed will be fundamentally different from life up until that point.

DNA nanosensors profile gene activity to reveal state of cells

A clever use of a simple DNA nanodevice demonstrates how relatively simple present day nanotech can contribute substantially to solving very important problems in biotechnology and medicine. A University of California – Santa Barbara press release available on EurekAlert! explains how. From “ Nanosensors made from DNA may light path to new cancer tests and drugs “: Sensors made from custom DNA molecules could be used to personalize cancer treatments and monitor the quality of stem cells, according to an international team of researchers led by scientists at UC Santa Barbara and the University of Rome Tor Vergata. The new nanosensors can quickly detect a broad class of proteins called transcription factors, which serve as the master control switches of life. The research is described in an article published in Journal of the American Chemical Society [ abstract — includes diagram of how device works]. “The fate of our cells is controlled by thousands of different proteins, called transcription factors,” said Alexis Vallée-Bélisle, a postdoctoral researcher in UCSB’s Department of Chemistry and Biochemistry, who led the study. “The role of these proteins is to read the genome and translate it into instructions for the synthesis of the various molecules that compose and control the cell. Transcription factors act a little bit like the ‘settings’ of our cells, just like the settings on our phones or computers. What our sensors do is read those settings.” When scientists take stem cells and turn them into specialized cells, they do so by changing the levels of a few transcription factors, he explained. This process is called cell reprogramming. “Our sensors monitor transcription factor activities, and could be used to make sure that stem cells have been properly reprogrammed,” said Vallée-Bélisle. “They could also be used to determine which transcription factors are activated or repressed in a patient’s cancer cells, thus enabling physicians to use the right combination of drugs for each patient.” … This international research effort –– organized by senior authors Kevin Plaxco, professor in UCSB’s Department of Chemistry and Biochemistry, and Francesco Ricci, professor at the University of Rome, Tor Vergata –– started when Ricci realized that all of the information necessary to detect transcription factor activities is already encrypted in the human genome, and could be used to build sensors. “Upon activation, these thousands of different transcription factors bind to their own specific target DNA sequence,” said Ricci. “We use these sequences as a starting point to build our new nanosensors.” … Transcription factors function by binding to a short sequence of DNA that regulates the activity of a class of genes, with each factor binding a different DNA sequence. This specific binding was used to turn a small DNA molecule into a specific biosensor. Specifically, the team re-engineered three naturally occurring DNA sequences, each recognizing a different transcription factor, into molecular switches that become fluorescent when they bind to their intended targets. Using these nanometer-scale sensors, the researchers could determine transcription factor activity directly in cellular extracts by simply measuring their fluorescence level. The researchers believe that this strategy will ultimately allow biologists to monitor the activation of thousands of transcription factors, leading to a better understanding of the mechanisms underlying cell division and development. “Alternatively, since these nanosensors work directly in biological samples, we also believe that they could be used to screen and test new drugs that could, for example, inhibit transcription-factor binding activity responsible for the growth of tumor cells,” said Plaxco.

Nanotechnology for Heart Repair Advances

In a major advance for the application of nanotechnology and tissue engineering to repair hearts suffering severe damage from a heart attack or coronary artery disease, gold nanowires added during the preparation of a tissue patch produced better, more functional heart patches. The advance is described in a PhysOrg.com article by Emily Finn “ A heart of gold: Better tissue repair after heart attack (Update) “: A team of researchers at MIT and Children’s Hospital Boston has built cardiac patches studded with tiny gold wires that could be used to create pieces of tissue whose cells all beat in time, mimicking the dynamics of natural heart muscle. The development could someday help people who have suffered heart attacks. The study, reported this week in Nature Nanotechnology [ abstract ], promises to improve on existing cardiac patches, which have difficulty achieving the level of conductivity necessary to ensure a smooth, continuous “beat” throughout a large piece of tissue. “The heart is an electrically quite sophisticated piece of machinery,” says Daniel Kohane, a professor in the Harvard-MIT Division of Health Sciences and Technology (HST) and senior author of the paper. “It is important that the cells beat together, or the tissue won’t function properly.” The unique new approach uses gold nanowires scattered among cardiac cells as they’re grown in vitro, a technique that “markedly enhances the performance of the cardiac patch,” Kohane says. The researchers believe the technology may eventually result in implantable patches to replace tissue that’s been damaged in a heart attack. … A blog article at Children’s Hospital Boston by Nancy Fliesler also describes the work “ Could nanotechnology improve treatment of heart attack and heart failure? “ People who have had a heart attack or have coronary artery disease often sustain damage that weakens their heart. Milder forms of heart failure can be treated with medications, but advanced heart dysfunction requires surgery or heart transplant. … Tissue-engineered cardiac patches are starting to go into clinical trials for heart patients. They’re made by seeding heart cells onto porous scaffolds that give the tissue shape and organization. But there’s one problem: The heart is an electrically conductive organ, and the scaffolding used for the patches isn’t conductive, so the tissue doesn’t contract as normal heart tissue does. Tal Dvir and Brian Timko, postdocs in both the Laboratory for Biomaterials and Drug Delivery at Children’s, headed by Daniel Kohane, and the lab of Robert Langer at MIT – came up with an idea: sprinkling tiny gold wires into the patches to enhance their electrical conductivity. The gold-laced patches … were thicker and their cells better organized. They had ramped-up production of proteins involved in muscle calcium binding and contraction and electrical coupling between cells. And, when stimulated with an electrical current, the cells produced a measurable spike in voltage. … A short YouTube video shows the dramatic difference in beating between a standard tissue engineered patch and one with gold nanowires. The bright green color in the video is a dye that shows the propagation of calcium ions through the tissue, tracking how the signals travel between heart cells. With gold nanowires added to the scaffold, the propagation distance of signals increased a thousand fold, from a few hundred micrometers to “many millimeters”—close what is seen in normal hearts where conduction occurs over centimeters. The article by Emily Finn concludes with an independent assessment from nanowire pioneer and winner of the 2001 Feynman Prize in Nanotechnology -Experimental, Charles Lieber: “I think other people can take advantage of this idea for other systems: In other muscle cells, other vascular constructs, perhaps even in neural systems, this is a simple way to have a big impact on the collective communication of cells,” Lieber says. “A lot of people are going to be jumping on this.” The article by Nancy Fliesler also describes a second nanotechnology-based approach to the treatment of heart attack and heart failure: But he and Dvir also have their eye on another approach, just reported in Nano Letters [ abstract ]. It uses nanotechnology to create tiny guided missiles that can be injected intravenously, circulate in the blood, then exit at the heart and target tissue damaged by heart attack. Many current experimental approaches to heart attack involve supplying growth factors, drugs, stem cells and other therapeutic agents to the scarred, dying tissue. Some of these compounds, such as periostin and neuregulin, have been shown in animal models to enhance heart regeneration and improve cardiac function. But the existing delivery approaches are all invasive, involving direct injections into the heart, catheter procedures, or surgical placement of implants that release the necessary factors. In this work, the researchers demonstrated that nanoparticles called liposomes could be specifically targeted to heart tissue that had suffered an infarction. A molecule that recognizes a protein made in large amounts after heart attacks was attached to the liposome surface, and the liposomes injected into mice with induced heart attacks. They bound only to scarred and not to healthy heart tissue.

Nanotechnology therapy for head and neck cancer shows promise

Dendrimers are chemically synthesized nanoparticles in which a branching monomer is polymerized to give tree-like structures organized around a central molecule, resulting in an atomically defined, more or less spherical nanostructure. The presence of many functional chemical groups on the dendrimer surface means these particles can easily be modified with molecules that provide added functionality to the dendrimer, such as molecules that target particular cells, and chemotherapy drugs as cargoes. Researchers at the University of Michigan have demonstrated in a model using immunocompromised mice (so that they do not reject human tumors) that dendrimers targeted to tumors and carrying anti-cancer drugs show great promise as potential therapy for head and neck cancer. From the National Cancer Institute Alliance for Nanotechnology in Cancer “ Polymeric Nanoparticles Attack Head and Neck Cancer “: Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. Now, researchers at the University of Michigan have developed a tumor-targeted nanoparticle that delivers high doses of anticancer agents directly to head and neck tumors. Tests in animals have shown that this novel formulation increases survival while triggering fewer side effects. Reporting its work in the Journal of Oral and Maxillofacial Surgery [ abstract ], a team led by James R. Baker, Jr., created a spherical polymeric nanoparticle known as a dendrimer to deliver the drug methotrexate to head and neck tumors. To target the nanoparticle to those tumors, the investigators decorated the nanoparticle’s surface with folic acid. Many tumors, but few healthy cells, produce excessive amounts of a folic acid receptor on their surfaces. … The researchers tested their dendrimer-based formulation in three different groups of mice. The control group had tumors grown from human head and neck tumors that did not produce the folic acid receptor. The two experimental groups had tumors grown from human head and neck tumors that expressed moderate and high levels of the folic acid receptor. Mice receiving the equivalent of three times the normally lethal dose of methotrexate, delivered on the dendrimer nanoparticle experienced none of the weight loss normally associated with methotrexate therapy. More importantly, dendrimer-delivered therapy produced marked gains in therapeutic response even in the mice whose tumors produced only moderate levels of folic acid receptor. Some additional information on targeted dendrimer cancer therapeutics is available from the Michigan Nanotechnology Institute for Medicine and Biological Sciences, including a free review article “ Dendrimer-based nanoparticles for cancer therapy “.

A four-artificial-neuron network from 112 DNA strands

Following up on their recent accomplishment of building a computational circuit from 74 small DNA molecules , Caltech researchers assembled 112 DNA strands into four artificial neurons that they trained with four pieces of information about four scientists. The artificial neural network can then play a game in which it properly answers questions about the identity of a scientist that the player has in mind even when the player gives it incomplete or wrong information. In this way it mimics the ability of a brain to make decisions based on incomplete information. The research was published in Nature [ abstract ]. The researchers have produced videos that explain their work ( Part I: design ; Part II: experiments ). From a Caltech news release written by Marcus Woo “ Caltech Researchers Create the First Artificial Neural Network Out of DNA: Molecular Soup Exhibits Brainlike Behavior “: … Researchers at the California Institute of Technology (Caltech) have now taken a major step toward creating artificial intelligence—not in a robot or a silicon chip, but in a test tube. The researchers are the first to have made an artificial neural network out of DNA, creating a circuit of interacting molecules that can recall memories based on incomplete patterns, just as a brain can. “The brain is incredible,” says Lulu Qian, a Caltech senior postdoctoral scholar in bioengineering and lead author on the paper describing this work, published in the July 21 issue of the journal Nature. “It allows us to recognize patterns of events, form memories, make decisions, and take actions. So we asked, instead of having a physically connected network of neural cells, can a soup of interacting molecules exhibit brainlike behavior?” The answer, as the researchers show, is yes. Consisting of four artificial neurons made from 112 distinct DNA strands, the researchers’ neural network plays a mind-reading game in which it tries to identify a mystery scientist. The researchers “trained” the neural network to “know” four scientists, whose identities are each represented by a specific, unique set of answers to four yes-or-no questions, such as whether the scientist was British. After thinking of a scientist, a human player provides an incomplete subset of answers that partially identifies the scientist. The player then conveys those clues to the network by dropping DNA strands that correspond to those answers into the test tube. Communicating via fluorescent signals, the network then identifies which scientist the player has in mind. Or, the network can “say” that it has insufficient information to pick just one of the scientists in its memory or that the clues contradict what it has remembered. The researchers played this game with the network using 27 different ways of answering the questions (out of 81 total combinations), and it responded correctly each time. This DNA-based neural network demonstrates the ability to take an incomplete pattern and figure out what it might represent—one of the brain’s unique features. … This is a promising milestone on the way to developing molecular computers to function inside living cells—analyzing the molecular environment inside the cell and taking appropriate action. Paper coauthor and Caltech professor Erik Winfree and colleague Paul W.K. Rothemund won the 2006 Feynman Prizes in Nanotechnology for both the experimental work and theory categories.

Medical nanorobots win poll on engineering’s Next Big Thing

Thanks to Robert A. Freitas Jr. for passing along this news item. NewScientist recently conducted a poll of its readers on What will be engineering’s Next Big Thing? . The answer to the question “ Which technology do you think will have the biggest impact on human life in the next 30 years? “: The clear winner with 3,097 votes — 35 per cent of the total — is Catherine McTeigue’s prediction of nanorobots that will repair cancerous cells: Nanorobots fight the medical battles of the future “Say the word “cancer” and people are fear-ridden. Projects being undertaken to harness nanotechnology and develop nanorobots to enter into the human body and repair cancerous cells, without the need for life-changing, disfiguring and painful chemotherapy, will have the greatest impact in the next 30 years. Watching loved ones suffer will be a thing of the past as the robots aid speedy recoveries, mortality rates drop, and as the technology is used more frequently, so will the cost, that oft deciding factor. An enormous step forwards for all mankind, in the form of a microscopic creature.” The winning suggestion is a bit vague as to just what kind of medical nanorobots are envisioned. Recent posts ( here , here , and here ) suggest that near-term, incremental nanotechnology could be successful in curing cancer by selectively killing cancer cells while sparing normal cells. However, the phrase “repair cancerous cells” suggests advanced medical nanotechnology, of the type Freitas has proposed , that could be capable of molecular level repair of cells rather than necessarily killing cancerous cells. On the other hand, using near-term nanotechnology to deliver into cancer cells siRNA or miRNA to alter cellular gene expression might also make it possible to “repair cancerous cells”. The next poll we would like to see is something to the effect of “How do you think medical nanorobots will be developed over the next 30 years?”